Table 2.
Demography and baseline characteristics of NO.MS cohort.
| Baseline characteristics | All patients | Cohort of patients by indication | ||
|---|---|---|---|---|
| Total (N = 34,957) | RRMS (N = 32,098) | SPMS (N = 1873) | PPMS (N = 986) | |
| Treatment naïve n (n/N′, %) |
N′ = 26,373 (75.4%) 5445 (20.6%) |
N′ = 23,564 (73.4%) 4282 (18.2%) |
N′ = 1832 (97.8%) 397 (21.7%) |
N′ = 977 (99.1%) 766 (78.4%) |
| Age (years) |
N′ = 34,928
(99.9%) 40.0 ± 10.6 |
N′ = 32,069
(99.9%) 39.3 ± 10.5 |
N′ = 1873
(100%) 47.6 ± 8.2 |
N′ = 986
(100%) 48.5 ± 8.5 |
| Sex | N′ = 34,955 (99.9%) | N′ = 32’096 (99.99%) | N′ = 1873 (100%) | N′ = 986 (100%) |
| Female, n (%) | 24,465 (70.0 %) | 22,865 (71.2 %) | 1123 (60 %) | 477 (48.8 %) |
| Male, n (%) | 10,490 (30.0 %) | 9231 (28.8 %) | 750 (40 %) | 509 (51.6 %) |
| MS since first symptoms (years) | N′ = 32,362 (92.6%) | N′ = 29,552 (92.1%) | N′ = 1826 (97.5%) | N′ = 984 (99.8%) |
| 0 to <2 | 4213 (13%) | 4201 (14.2%) | 5 (0.3%) | 7 (0.7%) |
| 2 to <5 | 6454 (19.9%) | 5968 (20.2%) | 99 (5.4%) | 387 (39.3%) |
| 5 to <10 | 8779 (27.1%) | 7891 (26.7%) | 334 (18.3%) | 554 (56.3%) |
| 10 to <30 | 12,210 (37.7%) | 10,909 (36.9%) | 1265 (69.3%) | 36 (3.7%) |
| 30 to <50 | 702 (2.2%) | 579 (2%) | 123 (6.7%) | 0 (0%) |
| 50 to <70 | 3 (0%) | 3 (0%) | 0 (0%) | 0 (0%) |
| 70 to <90 | 1 (0%) | 1 (0%) | 0 (0%) | 0 (0%) |
| EDSS |
N′ = 30,316
(86.7%) 2.9 ± 1.7 |
N′ = 27,488
(85.6%) 2.7 ± 1.6 |
N′ = 1852
(98.9%) 5.4 ± 1.1 |
N′ = 976
(99%) 4.6 ± 1.0 |
| Number of relapses last year |
N′ = 31,464
(90.0%) 1.2 ± 1.1 |
N′ = 29,624
(92.3%) 1.3 ± 1.1 |
N′ = 1827
(97.5%) 0.3 ± 0.6 |
N′ = 983
(99.7%) 0 ± 0.1 |
| Number of relapses last 2 years |
N′ = 30,809
(88.1%) 1.9 ± 1.7 |
N′ = 28,971
(90.3%) 2 ± 1.7 |
N′ = 1825
(97.4%) 0.8 ± 1.2 |
N′ = 983
(99.7%) 0 ± 0.2 |
| Patients with Gd+ T1 lesions, n (%) |
N′ = 12,926 (37.0%) 4399 (34.0 %) |
N′ = 10,227 (31.9%) 3884 (38.0 %) |
N′ = 1732 (92.5%) 391 (22.6 %) |
N′ = 967 (98.1%) 124 (12.8 %) |
| Number of Gd+ T1 lesions |
N′ = 12,926
(37.0%) 1.2 ± 3.5 |
N′ = 10,227
(31.9%) 1.3 ± 3.6 |
N′ = 1732
(92.5%) 0.9 ± 3.5 |
N′ = 967
(98.1%) 0.3 ± 1.0 |
| T2 lesion volume (mm3) |
N′ = 8883
(25.4%) 9963 ± 12,490 |
N′ = 6178
(19.2%) 8375 ± 10,764 |
N′ = 1738
(92.8%) 15,716 ± 16,227 |
N′ = 967
(98.1%) 9764 ± 12,014 |
| Normalised brain volume (cm3) |
N′ = 8735
(25.0%) 1473 ± 106 |
N′ = 6064
(18.9%) 1485 ± 110 |
N′ = 1708
(91.2%) 1421 ± 87 |
N′ = 963
(97.7%) 1492 ± 86 |
Gd+ T1: gadolinium-enhancing T1; PPMS: primary pogressive multiple sclerosis; RRMS: relapsing–remitting multiple sclerosis; SD: standard deviation; SPMS: secondary progressive multiple sclerosis.
Data are presented as mean ± SD, unless otherwise stated.